Is Teleflex stock a buy?

Teleflex has received a consensus rating of Buy.

What company owns UroLift?

Learn more at A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology.

Is Teleflex publicly traded?

Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery….Teleflex.

Type Public
Traded as NYSE: TFX S&P 500 Component
Industry medical device manufacturing
Headquarters Wayne, Pennsylvania , United States

Who bought NeoTract?

On September 5, 2017, the two companies announced a definitive agreement for Teleflex to acquire NeoTract in a transaction valued at up to $1.1 billion.

Is TFX a buy?

Out of 6 analysts, 3 (50%) are recommending TFX as a Strong Buy, 2 (33.33%) are recommending TFX as a Buy, 1 (16.67%) are recommending TFX as a Hold, 0 (0%) are recommending TFX as a Sell, and 0 (0%) are recommending TFX as a Strong Sell. What is TFX’s earnings growth forecast for 2021-2023?

Can Teleflex split?

According to our Teleflex stock split history records, Teleflex has had 2 splits. Teleflex (TFX) has 2 splits in our Teleflex stock split history database.

What is the success rate of UroLift?

Studies have also shown that unlike other BPH medications, the UroLift System helps preserve sexual function. The overall success rate of UroLift is high, with only 2-3% of men seeking retreatment each year.

Is UroLift permanent?

The UroLift System’s permanent implants, delivered during a minimally invasive outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

When did Teleflex go public?

1968: Listed on Toronto Stock Exchange.

Is NeoTract public company?

Founded in 2004, NeoTract is a privately-held medical device company that has developed and commercialized the FDA-cleared UroLift® System, a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH.

How is UroLift done?

An enlarged prostate compresses on the urethra, making it difficult for urine to flow. The UroLift Device is placed through the obstructed urethra to access the enlarged prostate. The device compresses the tissue and delivers tiny implants to lift and hold prostate tissue out of the way, thus opening the urethra.

Can UroLift be repeated?

Life After the Lift In the event additional treatment for BPH is needed later down the road, the UroLift procedure can be repeated, or men can undergo a traditional laser procedure. It’s also important to note that the UroLift procedure doesn’t interfere with prostate cancer treatment.